Accountable for driving Abbott's Regional Ethics and Compliance Program in Asia region across its hugely diversified businesses i.e. Nutritional Products, Diabetes Care, Medical Optics, Vascular, Diagnostics, Pharmaceuticals and Molecular. One goal in mind: Nurture a robust organisation wide mindset of Triple Lenses of Responsibilities Framework -- Ethics, Economics/Finance and the Law.

An accomplished International Ethics & Compliance professional with combined 18 years of proven track record from scaling up to sustaining the Compliance Program together with Global and Regional key stakeholders. Experienced leading complex Audits and Investigations that resulted in a more robust internal controls structure and FCPA/ Anti-Bribery Anti-Corruption detective and preventive measures being put in place.

An outstanding people manager whose leadership philosophy is having a clear vision, empowering, coaching and the right intervention.

A Harvard Business School trained and well regarded industry thought leader. Rhys is currently the co-chairperson for Asia Pharmaceutical Compliance Congress, faculty member of Seton Hall University's Asia-Pacific Healthcare Compliance Program, founding member of the Asia-Pacific Healthcare Compliance Industry Group and member of the Harvard Business School Healthcare Alumni Association.

Sabrina S. K. Chan is the Executive Director of the Hong Kong Association of the Pharmaceutical Industry (HKAPI).

She has been working industriously with different stakeholders, locally and regionally, to ensure patients' expedient access to innovative and effective medicine. She serves the healthcare community as the Chairlady of the Advisory Board of the Bachelor of Pharmacy Program of The University of Hong Kong, member of Business Facilitation Advisory Committee and member of the Pharmacy and Poison Board (Licensing Committee) of the Hong Kong SAR government. She has been mentor of APEC Business Ethics Project - the Biopharmaceutical Sector since 2012.

Sabrina studied Journalism and Law in Hong Kong, and got post-graduate degrees in International Studies/legal studies from The United Kingdom and China respectively.

Christopher Knight is the CEO of Everett Knight, providing multinational clients with strategic and commercial advice in Vietnam and Southeast Asia in the health and media sectors, and also the Senior Executive Advisor to the Board of the Pharmaceutical Research and Manufacturers Association in Thailand.

In both roles he advises the research based pharmaceutical sector on trade, compliance, and other related initiatives throughout Southeast Asia. He also works with governments and international health organizations on health and trade initiatives.

Prior to forming Everett Knight, he worked with PricewaterhouseCoopers, and with Arthur Andersen Legal as head of its Technology and Intellectual Property practice in Thailand, and in the legal services in Hong Kong and also monitored internal risk control for compliance with Sarbannes-Oxley.

Christopher has a Juris Doctorate and a Bachelors (Hons) degree in International Business. He is a member of several professional organizations including, the American Society of Law, Medicine and Ethics, and the Association Internationale des Juristes du Droit du Vin. Christopher has served on the American Chamber's Board of Governors for 4 years, and has been co-chairman on the Legislation Committee for AmCham Thailand since 2001 and chairman of the Health Committee for AmCham Hanoi.

Katsumi KOJIMA is a Corporate officer, Country Compliance officer Japan of Sanofi Group, based in Tokyo, Japan. He is a member of the Code Compliance Committee, the Japanese Pharmaceutical Manufacturers Association (JPMA) and a member of the International Federation of Pharmaceutical Manufacturers and associations (IFPMA) Code Compliance Network.

He has been working for compliance field in the pharmaceutical and medical device industries over ten (10) years. He engaged in a speaker and a panellist on compliance topics in various conferences, such as "How Do I Know It's Working? Key Performance Indicators, Metrics and More" at Asia-Pacific Economic Cooperation (Nanjing, China) in 2014, "Venues & Locations of Third Party Conferences: What is Appropriate" at Advanced Medical Technology Association and Medical Technology Association of Australia Compliance Conference (Singapore) in 2014 and "Australia and Japan transparency updates" at the Global MedTech Compliance Conference (Barcelona, Spain) in 2014.

He earned LLB from Waseda University (Tokyo, Japan) and LLM from Hitotsubashi University (Tokyo, Japan). In addition, he received certification from INSEAD Compliance Implementation Leadership 1 (Fontainebleau, France) and Seton Hall Law School Aisa-Pacific Healthcare Compliance (Singapore). Since 2010, he has served as a Visiting Lecturer at Kyoto Prefectural University of Medicine (Kyoto, Japan).

Henry J. Li, Legal Director and General Counsel of RDPAC, is a Chinese lawyer who has been in commercial law practice for over 25 years, with experience gained through working in China, Canada, US and Hong Kong, in both private practice and in-house positions. Before joining RDPAC, Henry has worked in senior positions with prestigious Chinese and international law firms such as C&C Law Office, Baker & McKenzie and Denton Hall, and business operations such as Accenture and Pfizer. Henry studied law at Law School of Peking University and Boalt Hall Law School of University of California at Berkeley.

Karen Eryou is currently Senior Director, Corporate Compliance, APAC for UCB. She has over 15 years of international work experience in the pharmaceutical industry including Clinical Operations, Quality Assurance, Auditing and Inspections, as well as Medical Affairs. She has focused on business practices, ethics and compliance topics for the past 5 years. Since 2011 Karen has been based in Shanghai where she was assigned to build the compliance function for UCB. Following the development and implementation of a comprehensive compliance program with the China team she now leads the compliance program for the Asia-Pacific region for UCB.

YUET MING THAM is a partner in Sidley's Hong Kong/Singapore offices. Ms. Tham has extensive experience advising a large number of major U.S./European pharmaceutical, medical devices and healthcare services companies on compliance, clinical trials, labeling, promotional and marketing regulations, as well as on a variety of contractual and commercial matters. Prior to joining Sidley, Ms. Tham was the Head of the Asia Life Sciences Group and the Asia Head of the Regulatory, Compliance and Investigations Group at another international law firm. She was previously the Asia Pacific Regional Compliance Director for Pfizer, during which she was responsible for compliance and investigations in Japan, China, Hong Kong, Australia, Korea, India, Taiwan and several Southeast Asian countries. Ms. Tham sits on the Advisory Board of Seton Hall University's Healthcare Compliance Program for Asia. She has been acknowledged as a "Leading Lawyer" by Chambers Asia Pacific in the Life Sciences, Dispute Resolution, Anti-Corruption and Contentious Financial Regulatory categories. She has also been listed by Who's Who Legal as a "Leading Business Lawyer" in three separate categories, namely Life Sciences, Business Crime Defense and Investigations. The 2016 edition regarded her as "One of the best-informed regulatory lawyers in the region" for the life sciences sector.

Keith Korenchuk is a partner in the FDA and Healthcare practice of Arnold & Porter, LLP in Washington D.C. He counsels and advises pharmaceutical, life sciences, medical device, biotechnology, and specialty pharmacy companies in the United States and worldwide on regulatory and compliance matters, including on the following matters:

• US and global compliance systems design, implementation, and ongoing assessment
• Regulatory matters involving healthcare professionals, including fraud and abuse, off-label promotion, False Claims Act and transparency related issues
• Global anti-bribery legislation, including the US Foreign Corrupt Practices Act, the Organization for Economic Co-operation and Development (OECD) Anti-bribery Convention, and related national implementing legislation
• Internal and government initiated investigations
• State legislation involving pharmaceutical and medical device marketing and disclosure
• Global, regional, and country specific codes of practice and conduct, including codes issues by Pharmaceutical Research and Manufacturers of America (PhRMA), AdvaMed, International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), and Eucomed
• Enterprise-wide risk management systems and programs
• Pharmaceutical price reporting and third party/managed markets negotiations

Karen Eryou is currently Senior Director, Corporate Compliance, APAC for UCB. She has over 15 years of international work experience in the pharmaceutical industry including Clinical Operations, Quality Assurance, Auditing and Inspections, as well as Medical Affairs. She has focused on business practices, ethics and compliance topics for the past 5 years. Since 2011 Karen has been based in Shanghai where she was assigned to build the compliance function for UCB. Following the development and implementation of a comprehensive compliance program with the China team she now leads the compliance program for the Asia-Pacific region for UCB.

Donald L. Ferrin is Professor of Organisational Behaviour and Human Resources at the Lee Kong Chian School of Business, Singapore Management University. He received his Ph.D. from the University of Minnesota's Carlson School of Management in 2000. Don's research focuses entirely on trust, including determinants and consequences of interpersonal trust, trust in leadership, trust development processes, trust in the context of networks, trust violations and trust repair strategies, effects of culture on trust, trust in the context of negotiation, trust in e-commerce, and group- and organization-level trust repair. Don currently serves as the Deputy Editor-in-Chief of the Journal of Trust Research.

Abdul is a specialist in anti-bribery and corruption compliance with more than 20 years in the life sciences industry. Currently at KPMG leading their UK ABAC compliance practice in their Life Science practice.

Prior to joining KPMG Abdul spent 15 years with Johnson & Johnson of which 10 were in healthcare compliance where he first led the compliance organisation for LifeScan across EMEA and latterly for J&J across the Asia Pacific region.

Originally an organic chemist, post-MBA Abdul has held posts in operations management and finance across the chemical, agrichemical and healthcare industries.

Sabina is a Consultant and an adjunct professor. She currently teaches a seminar on Legal and Ethical Issues in Sustainability at the Nanyang Technological University Business School and a seminar on Sustainability Strategy at the National University of Singapore. She operates out of Singapore and New Delhi. From 2010 to 2015, Sabina was the Vice-President and Compliance Officer (Pharma) with GlaxoSmithKline, based in Singapore for all markets ex US. From 2005 to 2010, Sabina was Director Ethics & Compliance Director, Pacific Asia and Africa at Abbott Labs, based also in Singapore. Sabina is admitted to practice law in Delhi, New York and Arizona. She obtained her Bachelor of Laws (LL.B.) at Delhi University and her Masters of Laws (LL.M,) at Columbia University, New York.

Albert van Maaren is Regional Compliance Officer for APAC (including China and Japan) for Merck KGaA. Albert has over 20 years of experience in the pharmaceutical field, including regulatory affairs, pharmacovigilance, quality assurance, market access, compliance and as Pharmaceutical Affairs Director of the Netherlands and Belgium.

Prior to his role in Singapore, Albert was also dedicated compliance officer for the Benelux countries and Portugal. Albert graduated with a Pharmaceutical degree from Utrecht University, the Netherlands, and completed his Executive Master of Compliance at VU University in Amsterdam.

Mohit is an Executive Director in Risk Consulting and leads the Life Sciences & Health Care industry in Southeast Asia. With 20 years of experience in Consulting and Life Sciences industries, he possesses in-depth expertise in enabling business growth strategies, transformations in Sales & Marketing, Finance and IT functions. He has extensive experience in delivering shared services, digital, enterprise applications and outsourcing initiatives.